Diligence memo · auto-generated · as of July 2, 2026
Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Relmada Therapeutics, Inc. operates in Pharmaceuticals, based in NEW YORK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Relmada Therapeutics, Inc. has raised $23M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $15M on 2014-05-12.
Most recent recorded round closed around 2014-05-12.
Valuation (modeled)modeled
Provath models Relmada Therapeutics, Inc. at approximately $512M (range $32M–$2.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.75× the median modeled value of Series B Pharmaceuticals companies in 2013–2015 (42 peers) — value vs value, same stage and era. Within the normal band (75% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 12.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 83.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 69% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 81% of those peers.
Closest niche peers: Lipocine Inc., CARDEAS PHARMA Corp, CoLucid Pharmaceuticals, Inc., Emisphere Technologies Inc, Vasculox, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.